The estimated Net Worth of W Gerald Austen is at least $32.9 Milion dollars as of 24 February 2015. W Austen owns over 6,000 units of Abiomed stock worth over $31,754,588 and over the last 21 years W sold ABMD stock worth over $1,098,120.
Sign up
W Austen ABMD stock SEC Form 4 insiders trading
W has made over 11 trades of the Abiomed stock since 2006, according to the Form 4 filled with the SEC. Most recently W sold 6,000 units of ABMD stock worth $363,720 on 24 February 2015.
The largest trade W's ever made was exercising 25,000 units of Abiomed stock on 20 July 2006 worth over $175,000. On average, W trades about 5,292 units every 131 days since 2003. As of 24 February 2015 W still owns at least 83,341 units of Abiomed stock.
You can see the complete history of W Austen stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's W Austen's mailing address?
W's mailing address filed with the SEC is , , , , .
Insiders trading at Abiomed
Over the last 21 years, insiders at Abiomed have traded over $148,507,587 worth of Abiomed stock and bought 232,354 units worth $4,276,073 . The most active insiders traders include Michael R Minogue, Eric A Md Rose oraz David M Weber. On average, Abiomed executives and independent directors trade stock every 16 days with the average trade being worth of $5,341,900. The most recent stock trade was executed by Martin P Sutter on 17 February 2022, trading 4,000 units of ABMD stock currently worth $1,258,840.
What does Abiomed do?
Abiomed Europe GmbH, Aachen / Germany, as affiliate of Abiomed Inc. headquartered in Danvers, Massachusetts, USA, is a leading medical technology company in the field of circulatory support. Its products aim to enable heart recovery by improving blood circulation and/or heart pump function.
What does Abiomed's logo look like?
Complete history of W Austen stock trades at Abiomed
Abiomed executives and stock owners
Abiomed executives and other stock owners filed with the SEC include:
-
Michael Minogue,
Chairman of the Board, President, Chief Executive Officer -
Todd Trapp,
Chief Financial Officer, Vice President -
Andrew Greenfield,
Vice President, Chief Commercial Officer -
David Weber,
Chief Operating Officer, Senior Vice President -
Michael R. Minogue,
Chairman, CEO & Pres -
Michael Howley,
Vice President and General Manager, Global Sales -
Todd A. Trapp,
CFO & VP -
Dr. David M. Weber,
Sr. VP & COO -
Marc A. Began,
VP, Gen. Counsel & Sec. -
Andrew J. Greenfield,
VP & Chief Commercial Officer -
Dorothy Puhy,
Lead Independent Director -
Paul Thomas,
Independent Director -
Martin Sutter,
Independent Director -
Jeannine Rivet,
Independent Director -
Christopher Van Gorder,
Independent Director -
Eric Rose,
Independent Director -
Marc Began,
Vice President, General Counsel, Secretary -
Karen Mahoney,
Head of Global HR -
Michael G. Howley,
VP & GM of Global Sales -
Sarah Karr,
Communications Mang. -
Ingrid Goldberg Ward,
Director of Investor Relations -
Dr. Thorsten Siess Ph.D.,
VP & CTO -
Henri A Termeer,
Director -
Gorder Chris Van,
Director -
William J Bolt,
SVP, DA and QA -
Michael John Tomsicek,
Vice President, CFO -
W Gerald Austen,
Director -
Myron L Rolle,
Director -
Louis E Lataif,
Director -
Robert Bowen,
Chief Financial Officer -
Ronald W Dollens,
Director -
Daniel J Sutherby,
CFO -
Inc Abiomed,
Director -
Connell Desmond Jr O,
Director -
Paul Fireman,
Director -
Javier Jimenez,
VP Operations -
Anthony W Bailey,
VP, Business Development -
David M Lederman,
Chairman, CEO & President -
Charles B Haaser,
Principal Financial Officer -
Eugene D Rabe,
SVP, Global Sales & Services -
Christopher D Macdonald,
SVP Global Sales -
Sheila Marie Flaherty,
VP, General Counsel -
Robert T V Kung,
SVP, Chief Scientific Officer -
Edward E Berger,
VP, Strat. Plan & Ext. Comm. -
Patricia A. Fitch,
Vice President of Sales -
Raymond J Kelley,
VP Marketing -
David Gottlieb,
Director -
John F Obrien,
Director -
Gary Stickel,
VP of HR -
Karim Benali,
VP Product Development -
Robert Farra,
VP Engineering & Manufacturing -
Stephen C Mc Evoy,
VP and General Counsel -
Paula A Johnson,
Director